Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 och 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - gikt - antigout preparat - duzallo är indicerat hos vuxna för behandling av hyperurikemi i gikt patienter som inte uppnått målet serum nivåer av urinsyra med en lämplig dos av allopurinol ensam.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 10 mg - rosuvastatinkalcium 10,4 mg aktiv substans; laktosmonohydrat hjälpämne - rosuvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 20 mg - rosuvastatinkalcium 20,79 mg aktiv substans; laktosmonohydrat hjälpämne - rosuvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 40 mg - laktosmonohydrat hjälpämne; rosuvastatinkalcium 41,6 mg aktiv substans - rosuvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; rosuvastatinkalcium 5,2 mg aktiv substans - rosuvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm healthcare a/s - allopurinol - tablett - 100 mg - glukos, flytande hjälpämne; laktos (vattenfri) hjälpämne; allopurinol 100 mg aktiv substans - allopurinol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - allopurinol - tablett - 100 mg - allopurinol 100 mg aktiv substans; laktosmonohydrat hjälpämne - allopurinol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm healthcare a/s - allopurinol - tablett - 300 mg - allopurinol 300 mg aktiv substans; glukos, flytande hjälpämne; laktos (vattenfri) hjälpämne - allopurinol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - allopurinol - tablett - 300 mg - laktosmonohydrat hjälpämne; allopurinol 300 mg aktiv substans; para-orange aluminiumlack hjälpämne - allopurinol